Gut Liver.
2024 Jan;18(1):3-4. 10.5009/gnl230505.
The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma
- Kim BK
1,2,3
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
- 3Yonsei Liver Center, Severance Hospital, Seoul, Korea
- KMID: 2551028
- DOI: http://doi.org/10.5009/gnl230505
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Advances in immune checkpoint inhibitors for hepatocellular carcinoma
- Gastrointestinal cancer treatment with immune checkpoint inhibitors
- Treatment of advanced urogenital cancers with immune checkpoint inhibitors
- Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report
